在儿科脑外固体瘤中对DNA修复途径的治疗向:当前状态和对免疫疗法的影响
Sophia J Zhao1, Daniel Prior1, Christine M Heske2
1Department of Pediatric Hematology/Oncology, Yale University School of Medicine, New Haven, CT 06510, USA.
Cancers
|May 11, 2024
概括
向DNA损伤修复 (DDR) 途径为儿科固体瘤提供了新的治疗策略. 利用DDR漏洞和结合DDR抑制剂可以提高治疗疗效,增强抗瘤免疫力.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 遗传学 是一个遗传学.
背景情况:
- DNA 损伤是癌症发展的关键驱动因素.
- 在癌症中,DNA损伤修复 (DDR) 途径的缺陷很常见,产生了可以针对治疗的依赖性.
- 小儿脑外固体瘤为DDR向治疗带来了独特的挑战和机会.
研究的目的:
- 审查DNA损伤修复 (DDR) 装置及其在瘤发生中的作用.
- 检查当前关于利用儿科脑外固体瘤中DDR通路漏洞的研究.
- 讨论单独或组合使用DDR抑制剂在癌症治疗和免疫治疗中的潜力.
主要方法:
- 对DNA损伤修复途径及其治疗向的文献综述.
- 对儿童癌症中DDR漏洞的当前研究进行评估.
- 对DDR抑制剂与化疗和免疫疗法的协同作用组合的评估.
主要成果:
- DDR缺陷会产生一种依赖,可以在治疗上加以利用.
- DDR抑制剂与化疗和免疫疗法的组合显示出有前途.
- 向DDR途径可能会增强瘤免疫性,并改善对免疫检查点封锁的反应.
结论:
- 针对DDR通路的向代表了对儿科固体瘤的有希望的治疗途径.
- 进一步的研究和临床试验对于验证DDR抑制剂在儿科瘤学中的疗效至关重要.
- 组合策略和免疫调节作用需要进行广泛的研究.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Nucleotide Excision Repair
3.5K
DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
3.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


